Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Green rooibos extract is a specialized, unfermented preparation of the South African plant *Aspalathus linearis*, processed to preserve high concentrations of the C-glucosyl dihydrochalcone aspalathin. Unlike traditional fermented red rooibos, the green extract maintains a distinct polyphenolic profile with potent antioxidant and metabolic-modulating properties. Its primary mechanism of action involves the activation of AMP-activated protein kinase (AMPK) and the upregulation of glucose transporter type 4 (GLUT4), which enhances glucose uptake and improves insulin sensitivity. Additionally, it has been shown to regulate lipid metabolism by suppressing lipogenic gene expression and reducing hepatic lipid accumulation. Developed primarily as a nutraceutical or dietary supplement, it is being investigated for its potential to treat type 2 diabetes, dyslipidemia, and metabolic syndrome, both as a monotherapy and as an adjunct to conventional pharmaceuticals like metformin or statins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on green rooibos extract.